Combination anti-Aβ treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice.


Drug development for Alzheimer's disease has endeavored to lower amyloid β (Aβ) by either blocking production or promoting clearance. The benefit of combining these approaches has been examined in mouse models and shown to improve pathological measures of disease over single treatment; however, the impact on cellular and cognitive functions affected by A… (More)
DOI: 10.1084/jem.20171484


  • Blog articles referencing this paper

  • Presentations referencing similar topics